Table 3.

Number of Stroke Events and Unadjusted Incidence Rates of Ischemic Stroke Over 11 Months of Follow-up, by Adherence to Direct Oral Anticoagulants and Warfarin Measured during Follow-up.

	DOAC Adherent Use	Warfarin Adherent Use	Combined Dual DOAC and Warfarin Adherent Use	Non-Adherent Use	Non-Use
Patient-years (% of Total Follow-up)	6,254 (19.6%)	4,944 (15.4%)	19 (0.06%)	3,497 (10.9%)	17,268 (54.0%)
No. Ischemic Stroke Events	75	88	0	67	471
Incidence Ischemic Stroke per 100 p-y (CI)	1.20 (0.96-1.50)	1.78 (1.44-2.19)	--	1.92 (1.51-2.43)	2.73 (2.49-2.99)

Abbreviations: DOAC=Direct Oral Anticoagulants; p-y=person-years.

Every day of the study, DOAC adherent use was defined as having at least 80% of the previous 30 days covered with DOACs. Warfarin adherent use was defined as having at least 80% of the previous 30 days covered with warfarin. Combined dual DOAC and warfarin use was defined as having at least 80% of the previous 30 days covered with oral anticoagulation, but less than 80% of them covered with DOACs and less than 80% covered with warfarin. Non-adherent use was defined as having more than 0% but less than 80% of the previous 30 days covered with oral anticoagulation. Non-use was defined as having 0% of the previous 30 days atrial covered with oral anticoagulation.

The proportion of follow-up indicates the proportion of the total follow-up for all study participants that was spent on each time-dependent treatment group.

The incidence of ischemic stroke was not estimated for the combined dual DOAC and warfarin adherent use because there were no events on this exposure category.